TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
暂无分享,去创建一个
P. Hainaut | P. Boffetta | D. Zaridze | A. Mukeria | R. Hung | P. Brennan | P. Tanière | J. Hunt | Florence le Calvez | Olaf Kelm
[1] R. L. Carter,et al. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans , 1980, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans.
[2] Roger A. Jones,et al. Endogenous 5-methylcytosine protects neighboring guanines from N7 and O6-methylation and O6-pyridyloxobutylation by the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2004, Biochemistry.
[3] P. Hainaut,et al. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. , 2001, The American journal of pathology.
[4] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[5] M. Thun,et al. Tobacco smoke and involuntary smoking. , 2004, IARC monographs on the evaluation of carcinogenic risks to humans.
[6] K. Kondo,et al. A dose‐response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients , 1996, Journal of surgical oncology.
[7] C. Prives,et al. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay , 1998, Oncogene.
[8] J. Samet,et al. Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.
[9] P. van de Putte,et al. Preferential repair and strand-specific repair of benzo[a]pyrene diol epoxide adducts in the HPRT gene of diploid human fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] S. Rodenhuis,et al. Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.
[11] J. Luketich,et al. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[12] J. Castelao,et al. Lung cancer and cyclooxygenase-2. , 2003, The Annals of thoracic surgery.
[13] V. Vasioukhin,et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. , 1997, Gastroenterology.
[14] A. Marchetti,et al. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. , 1998, British Journal of Cancer.
[15] H. Bartsch,et al. Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. , 1990, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[16] J H Ho,et al. Worldwide epidemiological patterns of lung cancer in nonsmokers. , 1990, International journal of epidemiology.
[17] R. Iggo,et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements , 2001, Oncogene.
[18] K. Kerr,et al. THE PATTERN OF K‐rasMUTATION IN PULMONARY ADENOCARCINOMA DEFINES A NEW PATHWAY OF TUMOUR DEVELOPMENT IN THE HUMAN LUNG , 1997, The Journal of pathology.
[19] N. Tretyakova,et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.
[20] W. Ahrens,et al. Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. , 1998, Journal of the National Cancer Institute.
[21] H. Becher,et al. Effect of tobacco smoking on various histological types of lung cancer , 2005, Journal of Cancer Research and Clinical Oncology.
[22] D. Dockery,et al. Risk of lung cancer from environmental exposures to tobacco smoke , 1997, Cancer Causes & Control.
[23] G. Pandya,et al. 1,N6-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. , 1996, Biochemistry.
[24] J. Yokota,et al. Molecular footprints of human lung cancer progression , 2004, Cancer science.
[25] C. Cross,et al. Nitric oxide: a pro-inflammatory mediator in lung disease? , 2000, Respiratory research.
[26] G. Pershagen,et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. , 2000, Cancer research.
[27] M. Tang,et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.
[28] S. Rodin,et al. On the origin of p53 G:C --> T:A transversions in lung cancers. , 2002, Mutation research.
[29] J. Minna,et al. Smoke exposure, histologic type and geography‐related differences in the methylation profiles of non‐small cell lung cancer , 2003, International journal of cancer.
[30] S. Hecht,et al. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.
[31] References , 1971 .
[32] W. Ahrens,et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. , 2001, Cancer research.
[33] M. Ridanpää,et al. K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos , 1993, International journal of cancer.
[34] Iarc Monographs,et al. Cumulative Index to IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. , 1986, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans.
[35] J. Minna,et al. p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. , 1998, British Journal of Cancer.
[36] C. Harris,et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.
[37] S. Tannenbaum,et al. Oxidation of 7,8-dihydro-8-oxoguanine affords lesions that are potent sources of replication errors in vivo. , 2002, Biochemistry.
[38] J. Jett,et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.
[39] W P Bennett,et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. , 1999, Journal of the National Cancer Institute.
[40] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[41] M. Tang,et al. Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.
[42] C. Harris,et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. , 2001, Cancer research.
[43] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[44] P. Hainaut,et al. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.
[45] S. Rodin,et al. Human lung cancer and p53: the interplay between mutagenesis and selection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] S. Kato,et al. Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* , 2004, Journal of Biological Chemistry.
[47] Tony Fletcher,et al. Assessing Exposure Misclassification by Expert Assessment in Multicenter Occupational Studies , 2003, Epidemiology.
[48] Toshihide Tsuda,et al. The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.
[49] Fredrik Nyberg,et al. Contribution of environmental factors to cancer risk. , 2003, British medical bulletin.
[50] A. Grollman,et al. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[51] I. Adcock,et al. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[52] T Paschke,et al. Analysis of different versions of the IARC p53 database with respect to G-->T transversion mutation frequencies and mutation hotspots in lung cancer of smokers and non-smokers. , 2000, Mutagenesis.
[53] M. Tang,et al. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers. , 2001, Cancer research.
[54] K. Shirato,et al. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. , 2000, American journal of respiratory and critical care medicine.